Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous iron isomaltoside vs oral polysaccharide iron in iron deficiency anemia
ChiCTR2300072661Phase 4Recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Jul 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: Hemoglobin. Started Jul 2022; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ChiCTR2300072661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072661.